Systematic review of management of chronic pain after surgery by Wylde, Vikki et al.
                          Wylde, V., Dennis, J., Beswick, A., Bruce, J., Eccleston, C., Howells, N., ...
Gooberman-Hill, R. (2017). Systematic review of management of chronic
pain after surgery. British Journal of Surgery, 104(10), 1293-1306.
https://doi.org/10.1002/bjs.10601
Publisher's PDF, also known as Version of record
License (if available):
CC BY-NC
Link to published version (if available):
10.1002/bjs.10601
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
http://onlinelibrary.wiley.com/doi/10.1002/bjs.10601/abstract. Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Systematic review
Systematic review of management of chronic pain after surgery
V. Wylde1 , J. Dennis1, A. D. Beswick1, J. Bruce3, C. Eccleston4,5, N. Howells2, T. J. Peters1 and
R. Gooberman-Hill1
1Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, and 2Avon Orthopaedic Centre, Department of Trauma and
Orthopaedics, North Bristol NHS Trust, Bristol, 3Warwick Clinical Trials Unit, University of Warwick, Warwick, and 4Centre for Pain Research,
University of Bath, Bath, UK, and 5Department of Experimental-Clinical and Health Psychology, Ghent University, Ghent, Belgium
Correspondence to: Dr V. Wylde, Musculoskeletal Research Unit, Learning and Research Building, Southmead Hospital, Bristol BS10 5NB, UK
(e-mail: v.wylde@bristol.ac.uk)
Background: Pain present for at least 3 months after a surgical procedure is considered chronic
postsurgical pain (CPSP) and affects 10–50 per cent of patients. Interventions for CPSP may focus on
the underlying condition that indicated surgery, the aetiology of new-onset pain or be multifactorial in
recognition of the diverse causes of this pain. The aim of this systematic review was to identify RCTs of
interventions for the management of CPSP, and synthesize data across treatment type to estimate their
effectiveness and safety.
Methods: MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Library were searched from
inception to March 2016. Trials of pain interventions received by patients at 3 months or more after
surgery were included. Risk of bias was assessed using the Cochrane risk-of-bias tool.
Results: Some 66 trials with data from 3149 participants were included. Most trials included patients
with chronic pain after spinal surgery (25 trials) or phantom limb pain (21 trials). Interventions were
predominantly pharmacological, including antiepileptics, capsaicin, epidural steroid injections, local
anaesthetic, neurotoxins, N-methyl-D-aspartate receptor antagonists and opioids. Other interventions
included acupuncture, exercise, postamputation limb liner, spinal cord stimulation, further surgery, laser
therapy, magnetic stimulation, mindfulness-based stress reduction, mirror therapy and sensory discrim-
ination training. Opportunities for meta-analysis were limited by heterogeneity. For all interventions,
there was insufficient evidence to draw conclusions on effectiveness.
Conclusion: There is a need for more evidence about interventions for CPSP. High-quality trials of
multimodal interventions matched to pain characteristics are needed to provide robust evidence to guide
management of CPSP.
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Introduction
Pain present for at least 3 months after a surgical procedure
is described as chronic postsurgical pain (CPSP)1. CPSP
affects between 10 and 50 per cent of patients after com-
mon operations such as mastectomy, cardiac surgery, hys-
terectomy, hernia repair, joint replacement, back surgery
and also moreminor procedures2–8. In a European survey9
of surgical patients, the prevalence of moderate to severe
CPSP at 12 months after operation was 11⋅8 per cent.
Chronic pain is associated with poor general health, dis-
ability, depression9–12 and social withdrawal, and increases
the risk of further co-morbidities13. CPSP has been defined
previously as pain that develops after surgery5, and a pro-
posed update to the definition includes the possibility that
CPSP is pain that increases in intensity after surgery14.
This update allows for the possibility that pain among
patients who undergo surgery to relieve pain is also, appro-
priately, included in the definition.
Risk factors for CPSP may be genetic, psychosocial,
or related to preoperative or acute postoperative pain
severity2,15. However, certain surgical procedure-related
factors are key for the development of chronic pain16.
Surgical procedures lasting longer than 3 h may increase
the risk of postoperative pain5. A major surgical factor
in the development of chronic pain is nerve injury, and
patients undergoing thoracic, breast and hernia surgery
are at particular risk of neuropathic pain8. Inflammation
resulting from intraoperative tissue injury can contribute
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to central sensitization and further pain2. Inadequate
preventive analgesia may also contribute17.
Knowledge of determinants and predictors of CPSP can
guide the development of interventions and help target
care. Possible forms of management for CPSP may focus
on the underlying condition that needed surgery, on the
aetiology of the pain, or be multifactorial in recognition
of the diverse causes of postoperative pain. Although some
forms of management may have limited applicability out-
side of the specific condition for which they were intended,
others may be transferrable, regardless of the surgical
procedure.
There are systematic reviews of pharmacological and
other interventions for the management of chronic pain,
defined generally, or specific to the presumed mechanisms
(such as neuropathic pain17 and cancer pain18). A number of
Cochrane reviews17,19–29 have included studies evaluating
interventions for CPSP, although this was not the primary
focus of these reviews. It is rare for any review to focus
specifically on chronic pain in the postoperative context.
Exceptions include reviews that have focused on interven-
tions for chronic pain after particular surgical procedures,
including phantom limb pain after amputation30 and knee
replacement31. The aim of the present review was to iden-
tify RCTs of interventions for the management of CPSP
and to synthesize data across treatment type to provide an
estimate of their effectiveness and safety. In keeping with
recommended practice, a systematic review is a key step
toward the development of future trials to evaluate inter-
ventions for CPSP32.
Methods
The protocol was registered in the international prospec-
tive register of systematic reviews (PROSPERO; http://
www.crd.york.ac.uk/PROSPERO/) on 15 January 2015
(registration number 15957). The review was conducted in
accordance with PRISMA guidelines33.
Eligibility criteria
Published articles describing RCTs involving any inter-
vention that aimed to provide management of CPSP were
included. Eligible studies reflected PICO criteria34:
patients aged 18 years or more and at least 90 per
cent of study participants reporting CPSP; interven-
tions for pain received by patients at a minimum of
3 months after surgery; comparison arm of placebo,
usual care or an alternative pain management interven-
tion; and outcomes were pain reported using any data
collection tool(s).
Information sources and searches
MEDLINE, Embase, PsycINFO, CINAHL and the
Cochrane Library were searched from inception to 23
March 2016. The search strategies were modified for
different bibliographic databases (Appendix S1, support-
ing information). No language restrictions were applied.
Reference lists were checked and registers inspected; grey
literature (literature not formally published as journal arti-
cles) was sought in OpenGrey (http://www.greynet.org/
opengreyrepository.html), a database of grey literature, on
30 March 2016. A minimum sample size was not specified
in the protocol to ensure inclusion of all treatments of
potential interest to clinicians and researchers working in
a range of surgical specialties.
Published conference abstracts were followed up to
obtain any full publications, but otherwise excluded.
After completion of data extraction, relevant systematic
reviews were identified from the Cochrane Database of
Systematic Reviews, and included studies were reviewed
to identify any studies missed in the initial searches
because eligibility was not apparent from the title
and abstract.
Study selection
All records identified in the search were imported into
EndNote X7 (Thomson Reuters, New York, New York,
USA). Abstracts or full-text articles were screened to
remove obviously irrelevant reports. Reasons for exclud-
ing studies were recorded as free text in EndNote X7.
This was performed by one author who was over-
inclusive if eligibility was not clear. A sample of 10
per cent was double screened by a second author, which
identified one eligible study that had been missed. The
final selection of studies was then performed in duplicate
by two authors. When there was insufficient information
to determine eligibility, study author e-mail addresses
were obtained and supplementary information was
requested.
Data collection
Data from included studies were extracted using stan-
dard forms by one author and checked by a second
author. Study setting, participant demographics, method-
ology, recruitment, duration, treatment characteristics,
length of follow-up, outcomes, tools used to measure
outcomes, and information for the risk-of-bias assess-
ment were recorded. Authors of studies were contacted
where necessary for clarification and to provide missing or
incomplete data.
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Outcomes
In accordance with GRADE guidelines35 and Cochrane
guidance, the total number of outcomes planned to be
included in this review was limited to seven (2 primary and
5 secondary). The primary clinical effectiveness outcome
was pain intensity and the primary harm outcome was
serious adverse events. These reflect recommendations
from the Initiative on Methods, Measurement, and Pain
Assessment in Clinical Trials (IMMPACT)36 and the
Cochrane Pain, Palliative and Supportive Care Review
Group (PaPaS)37. Studies were required to report the pri-
mary outcome of pain intensity to be eligible for inclusion
in the review. The first secondary outcome was the pres-
ence or absence of neuropathic pain, which is particularly
relevant to chronic pain after a surgical intervention8. The
other four secondary outcomes reflected the IMMPACT
core outcome domains for chronic pain clinical trials:
physical functioning, emotional functioning, participants’
ratings of global improvement and satisfaction with treat-
ment, and participant disposition36. No limits were placed
on the tools used to measure these outcomes.
Risk of bias in individual studies
Risk of bias was assessed using the Cochrane risk-of-bias
tool38. Two authors assessed the risk of bias independently
across the six domains of the tool for each study. Results are
reported through graphical representation of bias judge-
ments grouped by intervention.
Statistical analysis
In the protocol, meta-analyses were planned using
RevMan 5 (The Nordic Cochrane Centre, The Cochrane
Collaboration, Copenhagen, Denmark) with general guid-
ance from the Cochrane Handbook38. For dichotomous
(binary) data, the odds ratio with 95 per cent c.i. would
be used. For continuous data, if outcomes were mea-
sured identically across studies, an overall mean difference
and 95 per cent c.i. would be calculated. If continuous
outcomes were measured differently across studies, over-
all standardized mean differences and 95 per cent c.i.
would be calculated. For data from crossover trials, the
generic inverse-variance method in RevMan 5 would be
used.
Opportunities for meta-analysis were limited by hetero-
geneity between studies. Even when multiple studies
for a particular intervention were identified, variation
in modes of administration, comparator groups and/or
format of outcome data precluded pooling. Thus, the
majority of results are reported narratively, with results
of meta-analyses described only for gabapentin and
capsaicin. Planned subgroup analysis of pharmacotherapy,
physical/self-management and multidisciplinary interven-
tions was not possible owing to clinical andmethodological
heterogeneity. Results for pain outcome at final follow-up
within individual studies are presented as reported by
investigators (Tables S1 and S2, supporting information).
Results
Included trials
Searches identified 17 029 articles, of which 660 were
considered potentially relevant after initial screening.
Author e-mail addresses were traced for 57 of 78 stud-
ies that contained insufficient information to determine
eligibility, and further data were requested. Replies were
received for 16 studies, and only one was eligible for
inclusion. The remaining articles were assumed to be
ineligible as the abstract or full text made no reference to
patients having CPSP. After evaluation of full-text articles,
66 trials39–104 with data from 3149 participants were
included (Fig. 1).
An overall summary of trial characteristics is provided in
Table 1 and characteristics of individual trials are shown in
Tables S1 and S2 (supporting information). Table 2 summa-
rizes studies according to the index surgery and interven-
tion. Individual components of risk-of-bias assessment are
provided in Appendix S2 (supporting information).
Trial design
Trials were generally small, ranging in size from three to
250 participants (median 38). The study with three par-
ticipants was a pilot trial, but a total of 18 trials recruited
fewer than 20 participants. Sample size calculations were
reported in 34 of 66 studies; of these, 13 failed to recruit
or retain sufficient numbers of participants to meet their
calculation. Authors did not always state dates of recruit-
ment; publication dates ranged from 1989 to 2016. There
has been an increase over time in the number of published
trials in this field, from ten trials published before 2001 to
23 published between 2011 and 2015.
Interventions
The primary method of reporting results was grouped
according to treatment type. The majority of studies eval-
uated pharmacological interventions, and so studies were
grouped as primarily pharmacological, or as primarily
physical, surgical, psychological and other (Table 1).
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1293–1306
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Records excluded
n = 16 369
Full-text articles excluded n = 594
 Non-surgical population n = 206
 Not all patients postsurgical n = 139
 Not RCT n = 89
 Intervention delivered at < 3 months after surgery n = 72
 Conference abstract n = 47
 Additional publication of included study n = 18
 Unable to obtain n = 3
 Other n = 20
Records identified through
database searching
n = 19 636
Records identified through
other sources
n = 3
Records screened after duplicates removed
n = 17 029
Full-text articles
assessed for eligibility
n = 660
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Studies included in narrative synthesis
n = 62
Studies included in quantitative synthesis
(meta-analysis) n = 4
Fig. 1 Flow diagram showing selection of articles for review
Outcome measurements
A visual analogue scale (VAS) was used to assess pain inten-
sity in 37 of 66 studies (56 per cent). Validated pain-specific
tools were used infrequently; the most common was the
McGill Pain Questionnaire, which was used in eight stud-
ies. Only one trial referenced IMMPACT criteria36 for
patient outcomes. In terms of presentation of the pri-
mary outcome (pain intensity) as the percentage of patients
reporting 30 or 50 per cent improvement, a format pre-
ferred by both IMMPACT105 and the Cochrane PaPaS
Group106, only a minority of authors (6 of 31 trials pub-
lished after 2008) were compliant. Serious adverse events
and the secondary outcomes in this review were reported
inconsistently and there was no opportunity to summarize
these outcomes; therefore, only pain outcomes are pre-
sented in Tables S1 and S2 (supporting information).
Pharmacological interventions
Antidepressants
Four trials, including data from 177 participants, evalu-
ated the effect of antidepressants on chronic pain after
amputation39,40 or breast surgery41,42. Risk of bias was
evident in two studies owing to incomplete outcome
data40,42, and a change to the definition of responder and
potential funder bias40. Amitriptyline was evaluated in
three trials39,40,42, with some issues suggesting risk of bias,
and venlafaxine in one trial41 with a low risk of bias. There
was no evidence that a 4–6-week course of antidepressants
reduced pain intensity compared with placebo, except in
one trial42 involving 20 patients which found that patients
reported lower breast scar pain intensity after 4 weeks
of 100 mg/day amitriptyline compared with placebo.
However, this trial also found evidence that amitriptyline
resulted in more adverse events than placebo.
Antiepileptics
Eight trials including data from 338 participants evaluated
the effects of antiepileptic medications on CPSP. The
largest number of studies for any one technology was for
gabapentin (6 studies, 293 participants with pain after
amputation43,44, breast cancer surgery45, sternotomy46
and spinal surgery47,48). Four trials were at risk of bias
owing to issues relating to blinding48, blinding and
randomization45, incomplete outcome data44, and blind-
ing and single-authored article47. Meta-analysis using
the generic inverse-variance method was possible for the
primary outcome for one subgroup only (gabapentin versus
placebo for 6 weeks) involving two crossover trials with 43
patients43,44. This demonstrated a within-person mean dif-
ference in pain intensity measured on a VAS and numerical
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1293–1306
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Table 1 Overall summary of trial characteristics
Trial design Parallel design (41), crossover study (25)
No. of arms Two arms (53), three arms (12), five arms (1)
Countries USA (21), Germany (8), Denmark (7), Iran (3),
China (2), Egypt (2), Finland (2), France (2),
Italy (2), Korea (2), Sweden (2), Turkey (2),
Belgium (1), Canada (1), Israel (1),
Mozambique (1), The Netherlands (1),
Norway (1), Serbia (1), Spain (1), Switzerland
(1), UK (1), international multisite (1)
Surgery types Spinal surgery (25), amputation (21), breast
cancer surgery (8), inguinal hernia repair (3),
neck dissection for cancer (2), knee
replacement (1), sternotomy (1), abdominal
surgery (1), shoulder surgery (1), various
surgical procedures (3)
Interventions
Pharmacological Antidepressants as analgesics (4),
antiepileptics (8), capsaicin (3), epidural
steroid injections and associated
interventions (11), local anaesthetic (11),
neurotoxins (3), N-methyl-D-aspartate
receptor antagonist (7), opioids (6), calcitonin
(1), naloxone as an adjuvant to morphine (1)
Physical, surgical,
psychological and
other pain
management
Acupuncture/dry needling (2), exercise (4), limb
cover/liner for patients who had undergone
amputation (2), spinal cord stimulation (5),
further surgery (2), laser therapy (1),
magnetic stimulation (1), mindfulness-based
stress reduction (1), mirror therapy for
amputation (1), sensory discrimination
training (1), joint manipulation (1), combined
package of hot packs, ultrasound treatment
and transcutaneous electrical nerve
stimulation (1)
Comparator
interventions
Active treatment (31), placebo or sham (31),
usual care (2), waiting list (1), no treatment (1)
Values in parentheses are number of studies.
rating scale score of –1⋅12 (95 per cent c.i. –1⋅89 to –0⋅36;
I2 = 53 per cent), favouring gabapentin (Fig. S1, supporting
information). Similar results are reported in a Cochrane
review30 and no studies additional to those included in the
previous review were identified. The two trials that com-
pared gabapentin with non-steroidal anti-inflammatory
drugs (NSAIDs) found that gabapentin provided more
effective pain relief after 1 month46 and 6 months48 of
treatment. An 8-week course of gabapentin was found to
be superior to a stellate ganglion block using bupivacaine
in a trial involving 60 patients after mastectomy45. The
addition of 1 month of oral gabapentin to standard epidu-
ral corticosteroids was found to result in lower pain at 6
months compared with epidural corticosteroids alone after
spinal surgery47.
One trial49 with a low risk of bias found no differences in
pain relief between levetiracetam and placebo over 4 weeks
of treatment. Pain relief after taking pregabalin for 7 weeks
for chronic pain after abdominal surgery was compared
with placebo in a study of 13 patients50; results favouring
the treatment group must be interpreted with caution as
the trial was terminated early by the industry sponsor.
Capsaicin
Three trials including data from 174 participants eval-
uated capsaicin for relief of chronic pain after inguinal
hernia repair51, mastectomy52, and diverse procedures
for cancer53. All studies were at risk of bias because of
issues relating to blinding of a preparation with a burning
sensation and erythema. One study52 was also at risk of
bias owing to selective reporting. The trial51 assessing a
single 60-min application of a capsaicin patch (8 per cent)
found no evidence of pain relief compared with placebo
after 3 months. Two trials52,53 of low-dose (0⋅075 per cent)
capsaicin topical cream applied four times daily for 6–8
weeks reported some evidence of reduced pain intensity
compared with placebo. Meta-analysis suggested a modest
positive effect of capsaicin topical cream on the proportion
of patients reporting pain improvement (odds ratio 2⋅64,
95 per cent c.i. 1⋅02 to 6⋅86; I2 = 0 per cent) (Fig. S2,
supporting information), although caution is warranted
owing to risk of bias and, as a previous Cochrane review107
advised, the total number of events was too few to be
reliable. In both trials, a commonly reported side-effect
was local skin reaction.
Epidural injections and associated interventions
Eleven trials including data from 886 participants evaluated
epidural injections and associated interventions after spinal
surgery54–64. Risk of bias was evident in ten studies relating
to allocation concealment54–56,64, blinding54,58,61, incom-
plete outcome data54,57,61,63, selective reporting56,57,59,62
and single-authored article63. Two trials55,56 comparing
epidural injections with, and without steroids found no
difference in pain relief between groups. The addition of
steroids to 3-monthly morphine epidural injections was
not found to influence pain intensity after 6 months59. A
three-arm trial63 involving 206 patients evaluated epidural
injections of 1 mg indomethacin, 2 mg indomethacin and
80 mg methylprednisolone, and found that all treatments
resulted in a similar pain reduction. Two trials evaluating
epidural injections of steroids (prednisolone acetate) ver-
sus saline alone produced contrasting results: one57 noted
no benefit at 120 days and the other58 reported a reduc-
tion in pain at 18 months after multiple epidural injections.
The addition of hyaluronidase to an epidural steroid injec-
tion was found to lead to lower pain intensity at 4 weeks62
and 12 months60, and a combination of hyaluronidase and
triamcinolone provided more effective pain relief for 12
weeks than either agent alone61. Two trials reported that
adding percutaneous adhesiolysis to an epidural injection
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1293–1306
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Table 2 Summary of included studies according to the index surgery and intervention
Amputation
Spinal
surgery
Breast
cancer
Abdominal
surgery
Hernia
repair
Knee
replacement
Neck
dissection Sternotomy
Shoulder
surgery Mixed
Pharmacological interventions
Antidepressants 239,40 241,42
Antiepileptics 243,44 247,48 245,49 150 146
Capsaicin 152 151 153
Epidural injection and 1154–64
associated interventions
Local anaesthetic 470–73 267,68 245,74 265,66 169
Neurotoxins 177 175 176
NMDA receptor antagonist 678–83 169
Opioids 440,70,71,84 159 185
Other 178 186
Physical, surgical, psychological
and other interventions
Acupuncture/dry needling 188 187
Exercise 191 389,90,92
Limb cover/liner 293,94
Spinal cord stimulation 595–99
Surgery 290,95
Other 2102,104 392,100,103 1101
Nine trials40,45,59,69–71,90,92,95 were included twice or more as they evaluated interventions which fall into different categories. NMDA,
N-methyl-D-aspartate.
led to better pain relief at 6 months64 and 12months54 after
treatment.
Local anaesthetics
Eleven trials including data from 324 participants assessed
the effectiveness of local anaesthetics in providing pain
relief after inguinal hernia repair65,66, spinal surgery67–69,
amputation70–73 and breast cancer surgery45,74. Risk
of bias was evident in three studies, and concerned
incomplete outcome data73, random sequence generation
and blinding45, and early trial termination65. Inter-
ventions assessed included lidocaine block65, repeated
epidural nerve blocks68, stellate ganglion block45,74,
bupivacaine72, intravenous lidocaine67,69,70, ropivacaine73,
oral mexiletine71 and lidocaine patch66.
Five trials evaluated local anaesthetic nerve blocks. No
difference in pain intensity was found after ultrasound-
guided lidocaine nerve block compared with placebo
block65 or after repeated epidural sympathetic nerve block
compared with saline blocks68. A trial45 of stellate ganglion
blocks for pain after breast surgery found that they were
inferior to gabapentin; another trial74 noted that pain
relief at 8 weeks was improved with ultrasound guidance
compared with unguided blocks. One trial72 found that
injections of bupivacaine into contralateral painful muscle
sites that mirror phantom limb pains were more effective
at providing pain relief than placebo saline injections.
Five trials evaluated systemic administration of intra-
venous local anaesthetic or oral mexiletine. Two trials67,69
found that intravenous lidocaine did not reduce pain inten-
sity compared with saline, and one70 reported that it
reduced stump pain, but not phantom limb pain. A pilot
trial73 of three patients reported that ropivacaine reduced
phantom limb pain after 12 weeks, although no statisti-
cal tests were performed on this small patient sample. An
8-week course of oral mexiletine was found to have no
effect on pain intensity compared with placebo in a trial
with 60 patients71.
A single trial66 of 21 patients evaluated lidocaine patches
(5 per cent); applied for 2 weeks, they were found to
produce similar results to placebo patches.
Neurotoxins
Three trials including data from 91 participants evalu-
ated botulinum toxin A injections for chronic pain after
knee replacement75, neck dissection76 and lower limb
amputation77. One study77 had evidence of bias relating to
incomplete outcome data. In patients with knee replace-
ment treated with botulinum toxin A, pain intensity was
reduced compared with that in the placebo group after
2 and 7 months, with no increase in adverse events75.
In a dose-finding study76 involving patients with chronic
pain after neck dissection, a lower dose of botulinum A
toxin was associated with reduced pain intensity. There
was little evidence that botulinum A was more effec-
tive than lidocaine/Depo-Medrol® (Pharmacia &Upjohn,
New York, New York, USA) injection after 6 months in a
pilot trial of patients with phantom limb pain77.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2017; 104: 1293–1306
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N-methyl-D-aspartate receptor antagonists
Seven trials, including data from 122 participants, evalu-
atedN-methyl-D-aspartate (NMDA) receptor antagonists.
One study78 had evidence of risk of bias relating to blinding
and incomplete outcome data. No differences in pain relief
after 3–5 weeks of memantine compared with placebo
were found in four trials79–82 involving patients with pain
after amputation. Three studies, involving 11–20 patients
each, evaluated ketamine alone or in conjunction with
calcitonin with placebo for patients with phantom limb
pain78,83 or pain after diverse procedures69. All trials pro-
vided evidence that the intervention reduced pain intensity,
although follow-up was short (80 min to 48 h).
Opioids
Six trials including data from 297 participants evaluated
opioids for chronic pain after amputation40,70,71,84, breast
surgery85 and spinal surgery59. Opioids evaluated included
tramadol40, oral morphine71,84,85, morphine infusion70 and
epidural morphine59. In three trials, risk of bias was noted
relating to blinding84, incomplete outcome data40 and
selective reporting59. Compared with placebo, oral mor-
phine was found to provide better pain relief at 4–6
weeks70,71,84, although a common side-effect was constipa-
tion. Trials evaluating 4 weeks of tramadol compared with
placebo40, 6 weeks of morphine compared with gabapentin
with, or without NSAIDs85, and 3-monthly injections of
epidural morphine and steroids compared with steroids
alone59, found no differences in pain intensity between
treatment groups.
Other pharmacological interventions
One trial78, with risk of bias relating to blinding and incom-
plete outcome data, evaluated intravenous calcitonin for
phantom limb pain in 20 patients, and found no effect
up to 48 h after infusion compared with saline. Another
trial86, with no clear evidence of risk of bias, evaluated low
doses of oral/or intravenous naloxone as a supplement in
12 patients whose severe CPSP was already managed by
continuous intrathecal morphine administration. No evi-
dence of an effect on pain relief was found after two 3-week
sessions on differing doses of the drug across a 9-week
period
Physical, surgical, psychological and other
interventions
Acupuncture/dry needling
No evidence of differences in pain relief was found in a trial
of 20 patients comparing dry needling and physiotherapy
with physiotherapy alone for pain after shoulder surgery87.
Another trial88 involving 70 patients with chronic pain
after neck dissection reported that acupuncture resulted
in better pain relief than usual care after 42 days. Neither
participants nor assessors were blinded and this may have
introduced bias.
Exercise
Four trials89–92 involving 323 participants evaluated
exercise interventions, often as a component of a broader
package of care. Two studies were at risk of bias owing to
lack of blinding90,92. No evidence of differences in pain
relief was found in trials comparing 3 months of exercise
with, and without hyperextension exercises after lumbar
surgery89, and 3 weeks of exercise combined with a cogni-
tive intervention compared with lumbar fusion after disc
herniation surgery90. A 4-week training programme of
progressive muscle relaxation, mental imagery and phan-
tom exercises was found to be more effective at relieving
phantom limb pain than a general exercise programme91.
A trial92 of treatment of pain after laminectomy found
that 8 weeks of low-tech exercises (McKenzie-type and
spinal stabilization training exercise) or high-tech exercises
(cardiovascular, isotonic and isokinetic exercises) resulted
in a reduction in pain-related disability compared with no
treatment.
Limb cover/lining
One trial93 with 57 patients reported that non-invasive
limb covering for 12 weeks compared with sham limb
covering did not reduce phantom limb pain. Another trial94
involving 30 patients, which was at risk of bias owing to
incomplete outcome data, found evidence that a stump
liner worn by amputees for 2 weeks reduced pain compared
with a placebo liner.
Spinal cord stimulation
Five trials including 260 participants assessed the impact
of spinal cord stimulation (SCS) on chronic pain after
spinal surgery. Two studies95,96 had a risk of bias related to
blinding, and another97 owing to blinding and commercial
interests. Two trials found that patients who received SCS
for 6months reported better pain relief than those who had
conventional management (100 patients)97 or reoperation
(60)95. Subcutaneous stimulation as adjunct therapy to SCS
was noted to provide better relief of back pain, but not
leg pain, compared with sham treatment in a trial of 20
participants96. Burst SCS was found to be more effective
at providing pain relief after 1 week than tonic or placebo
SCS98. In a trial involving 15 patients99, there was no
difference in pain after 2 weeks on stimulation with 1000-
versus 500-Hz bursts.
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Surgery
No evidence of differences in pain relief was found when
lumbar fusion was compared with exercise for chronic pain
after disc herniation surgery in a trial of 60 participants90.
In a trial95 involving 60 patients with failed back surgery
syndrome, less pain relief after 6 months was reported by
patients who had reoperation than was reported by patients
who had SCS.
Other interventions
No evidence of differences in pain relief were found in
a trial of cutaneous magnetic stimulation for 24 h com-
pared with sham treatment after spinal surgery in 17
patients100. Four weeks of laser therapy compared with
placebo laser therapy was found to reduce mastectomy
pain at 12 weeks in a trial of 61 participants101. An
unblinded trial that included ten patients102, which was
at risk of bias, found that 2 weeks of sensory discrimi-
nation training led to a reduction in phantom limb pain
at 3 months compared with comprehensive psychophysio-
logical assessment. One trial103 with 40 patients, reported
that 8 weeks of mindfulness-based stress reduction follow-
ing spinal surgery led to better pain relief after 12 weeks
compared with that in the waiting list control group. How-
ever, the trial was at risk of bias because of lack of blinding
and incomplete outcome data. In a three-arm trial104 that
included 22 patients with phantom limb pain, mirror ther-
apy was found to reduce pain intensity after 4 weeks com-
pared with sham mirror therapy and mental visualization.
The study was at risk of bias owing to lack of blinding. A
trial92 involving patients with pain after laminectomy found
that an 8-week course of joint manipulation did not reduce
pain-related disability compared with no treatment. The
same trial also found no difference between a combined
package of hot packs, ultrasound treatment and transcuta-
neous electrical nerve stimulation, and no treatment.
Discussion
The best evidence to guide the implementation of effective
interventions comes from their evaluation in high-quality
randomized trials, and ultimately in systematic reviews
and meta-analyses. Given the prevalence and impact of
CPSP, it is imperative to establish robust methods for its
management. This systematic review aimed to provide
a comprehensive evaluation of the evidence base for the
management of CPSP. Although some of the interven-
tions identified were procedure-specific, others had wider
applicability to other types of CPSP. However, owing to
heterogeneity in the interventions and trial design, pooling
of data in meta-analysis was rarely possible or warranted.
Of the 66 included trials, most evaluated pharmacological
interventions. For all interventions, there was insufficient
evidence to draw conclusions on effectiveness or harm.
There are few systematic reviews in the field of
CPSP, with existing reviews focusing on predictors108,
characteristics8 and prevention109–112. The previ-
ous reviews that have evaluated treatments have been
procedure-specific, focusing on chronic pain after total
knee replacement31 and phantom limb pain30. This con-
trasts with other areas of pain research in which numerous
systematic reviews21,22,113–116 of treatments have been
published. Typically, the focus of a review is on a defined
condition (such as fibromyalgia, back pain) or a presumed
mechanism of chronic pain (for example neuropathic
pain). Patients with CPSP are, of course, embedded within
broader trials investigating chronic pain, but it has not
previously been possible to identify these patients.
This review highlighted some difficulties with conduct-
ing a broad systematic review of CPSP. First, there was
heterogeneity in the definition of CPSP within research
studies; some trials included only patients with neuropathic
pain and there was variability across studies in key eligibil-
ity criteria, such as duration and severity of pain. Second,
one-third of the studies included in the review evaluated
interventions for phantom limb pain. Although previous
reviews of CPSP have also included amputation109,111, the
commonality in the aetiology of phantom limb pain and
other forms of CPSP could be questioned. However, phan-
tom limb pain was included as the aim of this review was to
provide a broad overview of interventions for chronic pain
in the surgical context. The identification of interventions
that show effectiveness in one well studied surgical model
could provide directions for the evaluation of interventions
for CPSP in other surgical areas.
It is important to acknowledge the limitations of this
review when interpreting the results. Searches yielded a
large volume of literature and therefore initial eligibility
screening was performed in duplicate for only 10 per cent
of the studies; this may have increased the risk of eligible
studies being discarded117. However, the final selection
of studies was undertaken by two reviewers in accordance
with guidance from the Cochrane Handbook38. Given the
hidden nature of patients with CPSP included within other
trials, relevant studies were often difficult to identify from
titles and abstracts, and required investigation of the full
text to establish whether or not patients were likely to have
CPSP. Although the search terms identified a large volume
of literature, search of relevant Cochrane reviews identified
three other relevant studies that were not identified in the
initial searches. This highlights the difficulty of conducting
such a systematic review owing to limited reference to the
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patient sample by conventional means – there is no medi-
cal subject heading (MeSH) for CPSP, so indexers and even
study authors did not necessarily use CPSP as a descriptor
or keyword. Limits were not placed on the tools used
to assess secondary outcomes and the resulting hetero-
geneity precluded their inclusion in analysis. Adverse
events were found to be poorly and inconsistently reported.
This has previously been described as a common issue
in chronic pain trials30, and poor reporting precluded
conclusions about intervention safety in this review.
Opportunities for meta-analysis were limited because of
variability in the identified interventions, and conclusions
are predominantly based on narrative synthesis. However,
this review has produced a comprehensive overview of the
evidence for management of CPSP, and the findings have
a number of methodological and clinical implications.
Only three trials included patients with CPSP after
various surgical procedures; the remainder focused on
one surgery type. Of these, the majority of trials were
conducted to evaluate treatments for phantom limb pain
and failed back surgery syndrome, which is likely to reflect
the historical recognition of these pain conditions118,119.
Although an encouraging temporal increase in the number
of trials conducted was identified, the paucity of research
into the management of CPSP, particularly after opera-
tions other than amputation and spinal surgery, highlights
the need for further research. The majority of trials in this
review evaluated pharmacological interventions, reflecting
the commonplace role of these therapies in the manage-
ment of chronic pain. There was insufficient evidence
to evaluate the effectiveness of any treatment modality
in reducing CPSP. It has previously been proposed that
commonly prescribed pharmacological treatments are
insufficient to treat chronic non-cancer pain when used in
isolation120. Given the complex and multifactorial nature
of CPSP, an individualized and multimodal model of care
may be required, as recommended more widely for chronic
non-cancer pain120.
Similar to a previous review of interventions for phan-
tom limb pain30, the present analysis identified the need
for more methodological rigour in the reporting and
conduct of randomized trials in this field. This need
is highlighted by the unclear or high risk of bias rat-
ing assigned to many aspects of the included trials. Fre-
quently encountered issues included lack of transparency,
as shown by lack of preregistration of trials or publication
of trial protocols, failure to report conduct/results accord-
ing to CONSORT standards121–123, and limited and vari-
able assessment of pain and adverse events. IMMPACT
recommendations36 suggest the use of a comprehensive
approach to pain assessment in clinical trials addressing
chronic pain. Many of the trials included in this review
were conducted before publication of the IMMPACT rec-
ommendations in 2003. However, the trials conducted and
published after the IMMPACT guidance generally lim-
ited their outcome assessment to pain intensity. Incon-
sistent reporting of the secondary outcomes of interest
precluded their analysis, highlighting the need for stan-
dardization of outcomes assessment. For many included
trials, sample sizes were small and duration of follow-up
was short, limiting the conclusions that can be drawn
about the therapeutic benefit of interventions in the context
of chronic pain.
For many included trials, threats to both internal and
external validity existed. Reports of trials did not always
include a sample size calculation. The inclusion criteria did
not specify an a priori sample size, owing to the heterogene-
ity of the definition of CPSP and the range of potential
interventions. Such a broad approach allowed this review to
meet the intended aim of comprehensiveness, and to iden-
tify and present all trials within this complex and evolving
field, including those in which events led to early trial ter-
mination or lower recruitment than planned. In keeping
with recommendations in the Cochrane risk-of-bias tool,
sample size was not considered to present a risk of bias per
se124, although small studies do not improve the precision of
estimates. The relatively small sample sizes in some of the
studies that met the inclusion criteria, as well as the high
risk of bias among many of the largest trials, impacted on
both results and generalizability.
In addition to issues of bias in trial conduct and reporting,
the authors were initially keen to report on the quality
of the evidence, potentially using GRADE. However, this
was not possible because of the inability to estimate effects
of treatments: all findings would have been downgraded
for quality owing to the absence of evidence for synthesis.
However, as this field develops and more trials emerge,
it would be expected that new reviews will report effect
estimates and examine the quality of the evidence.
This review highlights the need for more evidence
about interventions for CPSP, and a focus not on the
presumed pathological mechanism or location of pain,
but on the relationship of pain to surgery. Many patients
experience CPSP and it is imperative that evidence-based
interventions are offered to these individuals to improve
postoperative outcome. Trials to date have focused on
pharmacological interventions, and no trials have been
conducted to evaluate multimodal interventions matched
to pain characteristics for the management of CPSP.
Given the complexity of pain that extends or emerges after
surgery, individualized interventions should be developed
and evaluated. High-quality trials of these interventions
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are needed to provide a robust evidence base to guide the
management of CPSP.
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